BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32690669)

  • 1. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.
    Clark PA; Sriramaneni RN; Jin WJ; Jagodinsky JC; Bates AM; Jaquish AA; Anderson BR; Le T; Lubin JA; Chakravarty I; Arthur IS; Heinze CM; Guy EI; Kler J; Klar KA; Carlson PM; Kim KM; Kuo JS; Morris ZS
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
    Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
    Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
    Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Baniel CC; Heinze CM; Hoefges A; Sumiec EG; Hank JA; Carlson PM; Jin WJ; Patel RB; Sriramaneni RN; Gillies SD; Erbe AK; Schwarz CN; Pieper AA; Rakhmilevich AL; Sondel PM; Morris ZS
    Front Immunol; 2020; 11():1610. PubMed ID: 32849544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
    Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course neoadjuvant in situ vaccination for murine melanoma.
    Aiken TJ; Komjathy D; Rodriguez M; Stuckwisch A; Feils A; Subbotin V; Birstler J; Gillies SD; Rakhmilevich AL; Erbe AK; Sondel PM
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
    Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model.
    Carlson PM; Mohan M; Rodriguez M; Subbotin V; Sun CX; Patel RB; Birstler J; Hank JA; Rakhmilevich AL; Morris ZS; Erbe AK; Sondel PM
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.
    Phadke MS; Li J; Chen Z; Rodriguez PC; Mandula JK; Karapetyan L; Forsyth PA; Chen YA; Smalley KSM
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
    Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
    Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor-Specific Inhibition of
    Morris ZS; Guy EI; Werner LR; Carlson PM; Heinze CM; Kler JS; Busche SM; Jaquish AA; Sriramaneni RN; Carmichael LL; Loibner H; Gillies SD; Korman AJ; Erbe AK; Hank JA; Rakhmilevich AL; Harari PM; Sondel PM
    Cancer Immunol Res; 2018 Jul; 6(7):825-834. PubMed ID: 29748391
    [No Abstract]   [Full Text] [Related]  

  • 13. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade.
    Mao C; Beiss V; Ho GW; Fields J; Steinmetz NF; Fiering S
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
    Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
    J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.
    Morris ZS; Guy EI; Francis DM; Gressett MM; Werner LR; Carmichael LL; Yang RK; Armstrong EA; Huang S; Navid F; Gillies SD; Korman A; Hank JA; Rakhmilevich AL; Harari PM; Sondel PM
    Cancer Res; 2016 Jul; 76(13):3929-41. PubMed ID: 27197149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
    Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
    Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
    PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
    Belcaid Z; Phallen JA; Zeng J; See AP; Mathios D; Gottschalk C; Nicholas S; Kellett M; Ruzevick J; Jackson C; Albesiano E; Durham NM; Ye X; Tran PT; Tyler B; Wong JW; Brem H; Pardoll DM; Drake CG; Lim M
    PLoS One; 2014; 9(7):e101764. PubMed ID: 25013914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.